← Yarrow Bioscience, Inc. (YARW) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Yarrow Bioscience, Inc. (YARW)
Pharmaceutical Preparations · market cap $236M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
17
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Serlopitant High Dose | Phase 2 | Pruritus |
| VPD-737 | Phase 2 | Chronic Pruritus |
| FMX101 | Phase 3 | Acne Vulgaris |
| MK0594 | Phase 2 | Urinary Incontinence |
| Minocycline Foam | Phase 2 | Acne Vulgaris |
| YB-101 | Phase 2 | Graves' Disease |
| Topical Minocycline Foam FXFM244 | Phase 2 | Acne Vulgaris |
| serlopitant | Phase 2 | Prurigo Nodularis |
| FMX-101, minocycline foam | Phase 3 | Acne Vulgaris |
| FMX103 minocycline foam | Phase 3 | Facial Papulopustular Rosacea |
| FMX103 | Phase 3 | Papulopustular Rosacea |
| VYN201 Gel | Phase 2 | Non-segmental Vitiligo |
| FMX114 | Phase 2 | Atopic Dermatitis |
| FMX-103 | Phase 2 | Rosacea |
| Serlopitant Tablet | Phase 2 | Epidermolysis Bullosa |
| ARK-E021 | Phase 2 | Acne Vulgaris |
| FDX104 (Doxycycline) | Phase 2 | Rash Due to Epidermal Growth Factor Receptor Inhibitors |
Price & technical context
3-month
-40.8%
6-month
-37.9%
12-month
+14.7%
52-wk range
$16.40–$46.15
vs 50-day MA
-22.2%
vs 200-day MA
-35.3%
Realized vol
91.5%
Max drawdown
-93.3%
Daily closes through 2026-10-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for YARW (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.